Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP)

H. W. Bruckner, C. J. Cohen, G. Deppe, B. Kabakow, R. Wallach, L. Ratner, James F. Holland

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

A four-drug regimen consisting of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (II) (CHAP) produced three complete clinical and seven partial responses for 21 patients with adenocarcinoma of the ovary after objective progression of disease during treatment with standard chemotherapy. Median survival was 15 months for responders and 7 months for all patients.

Original languageEnglish
Pages (from-to)150-153
Number of pages4
JournalGynecologic Oncology
Volume12
Issue number2
DOIs
StatePublished - Oct 1981
Externally publishedYes

Fingerprint

Dive into the research topics of 'Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP)'. Together they form a unique fingerprint.

Cite this